Royal Bank Of Canada Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target reduced by stock analysts at Royal Bank Of Canada to $1.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “sector perform” rating on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 122.22% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald downgraded Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Monday, August 17th. Chardan Capital lowered Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 target price on the stock. in a research note on Tuesday, August 18th. Stifel Nicolaus began coverage on Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They set a “buy” rating and a $40.00 target price on the stock. Wall Street Zen raised Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, September 27th. Finally, HC Wainwright reissued a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $21.85.

Eyepoint Pharmaceuticals Price Performance

Eyepoint Pharmaceuticals stock traded up $0.01 during trading on Tuesday, reaching $0.45. 17,751,561 shares of the company were exchanged, compared to its average volume of 3,118,077. Eyepoint Pharmaceuticals has a 52-week low of $0.40 and a 52-week high of $19.11. The company has a market capitalization of $38.79 million, a P/E ratio of -0.12 and a beta of 1.67. The stock’s 50 day simple moving average is $4.77 and its two-hundred day simple moving average is $10.30.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%. The company had revenue of $0.51 million for the quarter, compared to analysts’ expectations of $0.45 million. As a group, equities analysts forecast that Eyepoint Pharmaceuticals will post -3.51 earnings per share for the current year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several hedge funds have recently bought and sold shares of EYPT. Commodore Capital LP acquired a new position in Eyepoint Pharmaceuticals during the 1st quarter worth about $36,414,000. Hsbc Holdings PLC purchased a new stake in Eyepoint Pharmaceuticals during the 1st quarter worth about $10,743,000. Janus Henderson Group PLC increased its holdings in Eyepoint Pharmaceuticals by 22.6% during the 1st quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after purchasing an additional 663,439 shares during the period. Stempoint Capital LP increased its holdings in Eyepoint Pharmaceuticals by 129.1% during the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after purchasing an additional 456,915 shares during the period. Finally, Walleye Capital LLC purchased a new stake in Eyepoint Pharmaceuticals during the 1st quarter worth about $3,869,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals News Summary

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Some analysts see potential recovery value at the current price. Mizuho maintained its neutral rating while assigning a $0.50 price target, and Jefferies moved to hold with a $1.00 target. These targets imply substantial upside from the current $0.44 level, although both firms remain cautious. TickerReport analyst coverage
• Positive Sentiment: Unusual options activity included the purchase of 7,885 call contracts, about 69% above typical daily volume, suggesting some traders are positioning for a potential rebound. However, options activity is not confirmation of a fundamental recovery.
• Neutral Sentiment: HC Wainwright and Mizuho reaffirmed neutral ratings. Their stance indicates limited conviction that the remaining pipeline currently supports a bullish investment case.
• Negative Sentiment: JPMorgan downgraded EyePoint from neutral to underweight, while Guggenheim cut its rating from buy to neutral. The downgrades reflect reduced confidence after the LUCIA setback.
• Negative Sentiment: EyePoint is cutting 53% of its workforce and halting wet AMD clinical trials early after disappointing LUCIA results. The company is redirecting resources toward DURAVYU’s diabetic macular edema program, but the restructuring underscores the loss of a major development catalyst. Benzinga workforce and clinical-trial report
• Negative Sentiment: Levi & Korsinsky announced an investigation into potential securities-law violations on behalf of shareholders who suffered losses after the trial disclosure. The investigation adds legal and reputational risk. Levi and Korsinsky investigation notice

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing therapies for serious eye diseases. The company specializes in sustained-release drug delivery technologies designed to provide extended treatment in the eye and potentially reduce the frequency of injections or other interventions.

EyePoint’s commercial products include YUTIQ, an intravitreal implant that delivers fluocinolone acetonide for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, an intraocular suspension of dexamethasone used to treat postoperative inflammation following ocular surgery.